{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-23-000045","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.264441+00:00","generated_at":"2026-06-15T03:41:33.938168+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ClearPoint Neuro Q1 revenue $5.4M (+8% YoY); biologics/drug delivery +24%; reaffirms FY23 guidance $25-27M","bullets":["Revenue $5.4M (+8% YoY); biologics and drug delivery revenue $2.7M (+24% YoY) drove growth.","Gross margin fell to 59% from 64% due to higher biologics services costs and overhead.","Operating expenses $8.9M vs $7.1M, driven by headcount and stock-based compensation increases.","Cash and short-term investments $31.7M, down from $37.5M; operating cash used $5.7M in quarter.","Reaffirmed full-year 2023 revenue guidance of $25-27M, implying 22-35% YoY growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-23-000045","json":"https://secwatch.observer/filing/0001285550-23-000045.json","markdown":"https://secwatch.observer/filing/0001285550-23-000045.md","text":"https://secwatch.observer/filing/0001285550-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/0001285550-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/clpt-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:41:33.938168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbd73468f05da51c6e957ce2834f47493ed73415","claim":"ClearPoint Neuro, Inc. reported first quarter ended March 31, 2023 results: revenue $5.4 million. Guidance reaffirmed.","evidence_excerpt":"navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2023. First Quarter Highlights • Reported quarterly revenue of $5.4 million, a 8% year-over-year increase; • Increased biologics and drug delivery revenue to $2.7 million, a 24% year-over-year increase; • Announced exclusive multi-year licensing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/0001285550-23-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$5.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}